Integrating Pharmacogenomics into Clinical Practice: A Path to Personalized Prescribing
4 July 2025
A recent review published in PMC highlights the increasing recognition and potential of Pharmacogenomics (PGx) in transforming healthcare. This is particularly true and notable because it was an honor to have had such an opportunity by getting involved with hospitals. Our recent visit to Indonesia inspires communities and patients to know more about their genetic makeup through our PRECISE Pharmacogenomics (PGx) testing.
As our understanding of the human genome expands, so does the opportunity to tailor medical treatments to an individual’s unique genetic makeup. This personalized approach, with the assistance of Pharmacogenomics testing, is becoming crucial for optimizing drug therapy and improving patient outcomes.
The Promise of Pharmacogenomics (PGx)
Pharmacogenomics testing examines how a person’s genes affect their response to drugs or common medications that are prescribed to people. It’s fascinating to know that variations in specific genes can influence how drugs are absorbed, metabolized, distributed, and eliminated from the body. This is the breakdown of what your body is going through. However, this is not the complete breakdown, as it also involves your genes, which you can learn more about ADME.
By identifying these genetic variations, healthcare professionals can;
Predict drug efficacy
It’s to determine if that ‘one‘ SPECIFIC medicine is effective for the patient.
Minimize adverse drug reactions (ADRs) or medication side effects
This enables healthcare providers and professionals to identify individuals who are at RISK of experiencing side effects from the medication.
Optimizes drug dosages
Drug dosages are tailored to achieve the best therapeutic effect with the least toxicity. What it means is basically your medications are CUSTOMIZED, fitting the right requirements from your pharmacogenomics report.
Bridging the Gap: From Research to Routine Care
While the scientific foundation for Pharmacogenomics is robust, its widespread adoption into routine clinical practice still faces challenges. The PMC review emphasizes the need to continue efforts to:
- Educate healthcare professionals: Equip clinicians with the knowledge and tools to interpret Pharmacogenomics test results and apply them in patient care. We have conducted CME sessions, also known as Continuous Medical Education, to inspire healthcare professionals about the benefits of PRECISE Pharmacogenomics, which implements clinically actionable insights.
- Develop clear clinical guidelines: Establish standardized recommendations for when and how Pharmacogenomics testing should be used for various medications and conditions. Imagine this – visiting your frequent clinic and having your doctor prescribe the right medication for you.
- Electronic Health Records (EHRs): Facilitate seamless access to genetic information at the point of care, enabling informed prescribing decisions. PreciseEHR is one of our in-house apps that ensures your report is accessible and convenient.
- Address economic considerations: Demonstrate the long-term cost-effectiveness of PGx testing through improved patient outcomes and reduced healthcare expenditures. Multiple trips to the hospital are not an ideal approach unless it is necessary, but knowing your necessary medications allows patients to save time and money in the long run.
The Future of Healthcare is Personalized
The push to integrate Pharmacogenomics into daily medical practice is not just about adopting a new technology; it’s about evolving towards a more precise and patient-centric healthcare model.
For healthcare professionals, embracing Pharmacogenomics means moving beyond the “one-size-fits-all” approach to medication and instead offering truly personalized medicine. This shift promises to enhance treatment effectiveness, reduce adverse events, and ultimately, improve the quality of life for countless patients.
As Pharmacogenomics testing becomes more accessible and its benefits more widely recognized, its implementation will be a cornerstone in the journey towards a future where every patient receives the most optimal and safest treatment for their individual needs.
Reference
Preys, C. L., Zawatsky, C. L. B., Massmann, A., Van Heukelom, J., Green, R. C., Hajek, C., Hickingbotham, M. R., Zoltick, E. S., Schultz, A., & Christensen, K. D. (2023). Attitudes about Pharmacogenomic Testing Vary by Healthcare Specialty. Pharmacogenomics, 24(10), 539–549. https://doi.org/10.2217/pgs-2023-0039
